Last reviewed · How we verify

NCT05185037

NIBP (Non-invasive Blood Pressure) Algorithm Enhancements (Characterize the Robustness of Motion Artifact Suppression)

Terminated Last updated 5 January 2024
What this trial tests

trial testing Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes) in Movement, Involuntary in 17 participants. Terminated before completion.

Timeline
26 May 2022
Primary endpoint
16 November 2023
16 November 2023

Quick facts

Lead sponsorPhilips Clinical & Medical Affairs Global
StatusTerminated
Study typeOBSERVATIONAL
Enrollment17
Start date26 May 2022
Primary completion16 November 2023
Estimated completion16 November 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Philips Clinical & Medical Affairs Global — full company profile →

Who can join

18 and older, female only, with Movement, Involuntary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study intervention consists of a non-invasive blood pressure (NIBP) measurement device and cuff (FDA-cleared Philips IntelliVue X3 Rev. N.04 patient monitor) running a non-approved modified software containing an enhanced measurement algorithm for NIBP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Philips Clinical & Medical Affairs Global trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05185037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing